Activating a collaborative innate-adaptive immune response to control metastasis.
暂无分享,去创建一个
P. Gimotty | S. Adams | I. McNeish | D. Spector | M. Egeblad | Bodu Liu | Lijuan Sun | Tim Kees | A. S. Almeida | Xiao Han | D. Ng | Xue-Yan He | David Ng
[1] S. Hannenhalli,et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis , 2021, Cell.
[2] Sean C. Bendall,et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity , 2020, Nature Cancer.
[3] Amy L. Olex,et al. Regulatory T Cells Support Breast Cancer Progression by Opposing IFN-γ-Dependent Functional Reprogramming of Myeloid Cells. , 2020, Cell reports.
[4] Wei Zhang,et al. Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies , 2020, Cancer Immunology, Immunotherapy.
[5] T. Doman,et al. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study , 2020, Clinical Cancer Research.
[6] Elias A. Rahal,et al. Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model , 2020, Frontiers in Oncology.
[7] E. Song,et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25 , 2020, Nature.
[8] I. Melero,et al. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. , 2019, Cancer cell.
[9] Aditi Gupta,et al. In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. , 2019, The Journal of clinical investigation.
[10] F. Marincola,et al. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod , 2019, Scientific Reports.
[11] J. Joyce,et al. Re-education of macrophages as a therapeutic strategy in cancer. , 2019, Immunotherapy.
[12] J. Varner,et al. Targeting Tumor-Associated Macrophages in Cancer. , 2019, Trends in immunology.
[13] J. Pollard,et al. Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.
[14] Michael S. Goldberg,et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice , 2018, Science.
[15] D. Fearon,et al. Cancer cell CCR2 orchestrates suppression of the adaptive immune response , 2018, bioRxiv.
[16] B. Vanderhyden,et al. The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy , 2018, Cancers.
[17] M. Oliveira,et al. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..
[18] J. Pollard,et al. A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation , 2018, Cell reports.
[19] W. Woodward,et al. Inflammatory breast cancer biology: the tumour microenvironment is key , 2018, Nature Reviews Cancer.
[20] Michael F. Cuccarese,et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy , 2018, Nature Biomedical Engineering.
[21] N. Bercovici,et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment , 2018, Proceedings of the National Academy of Sciences.
[22] T. Kitamura,et al. Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors , 2018, Front. Cell Dev. Biol..
[23] N. Carragher,et al. Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer , 2018, Front. Immunol..
[24] M. Croft,et al. TNF activity and T cells. , 2018, Cytokine.
[25] A. Letai,et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages , 2017, Nature.
[26] R. Müller,et al. Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure. , 2017, Trends in cancer.
[27] C. Ries,et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, Journal for immunotherapy of cancer.
[28] Philippe Foubert,et al. PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.
[29] L. Chow,et al. Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN , 2016, Clinical Cancer Research.
[30] Wang Min,et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. , 2016, The Journal of clinical investigation.
[31] I. McNeish,et al. CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. , 2016, Cancer research.
[32] Cheryl L. Sershen,et al. Investigating the Role of TNF-α and IFN-γ Activation on the Dynamics of iNOS Gene Expression in LPS Stimulated Macrophages , 2016, PloS one.
[33] M. Prados,et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. , 2016, Neuro-oncology.
[34] P. Hertzog,et al. Optimizing mouse models for precision cancer prevention , 2016, Nature Reviews Cancer.
[35] D. Kaufman,et al. Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. , 2016 .
[36] M. van de Rijn,et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. , 2015, The New England journal of medicine.
[37] L. Zitvogel,et al. Autocrine signaling of type 1 interferons in successful anticancer chemotherapy , 2015, Oncoimmunology.
[38] L. Zitvogel,et al. Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.
[39] Shinn-Jang Hwang,et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. , 2015, The New England journal of medicine.
[40] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[41] Vivien W. Chan,et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.
[42] Wei Shi,et al. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..
[43] Thomas A. Wynn,et al. Macrophage biology in development, homeostasis and disease , 2013, Nature.
[44] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[45] S. Demaria,et al. Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer , 2012, Clinical Cancer Research.
[46] Jae-Hyun Park,et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.
[47] Mikala Egeblad,et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. , 2012, Cancer cell.
[48] K. Goa,et al. Interferon Gamma-1b , 2012, Drugs.
[49] Karin Jirström,et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.
[50] D. Zamboni,et al. A Method for Generation of Bone Marrow-Derived Macrophages from Cryopreserved Mouse Bone Marrow Cells , 2010, PloS one.
[51] C. Figdor,et al. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. , 2010, Gynecologic oncology.
[52] J. Zwaginga,et al. Monophosphoryl lipid A plus IFNγ maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential , 2010, Cancer Immunology, Immunotherapy.
[53] S. Adams. Toll-like receptor agonists in cancer therapy. , 2009, Immunotherapy.
[54] M. Croft. The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.
[55] W. Yeh,et al. LPS/TLR4 signal transduction pathway. , 2008, Cytokine.
[56] Chien-Fu Hung,et al. Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer , 2008, Biologics : targets & therapy.
[57] Thomas C. Mitchell,et al. The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.
[58] T. Herzog. The current treatment of recurrent ovarian cancer , 2006, Current oncology reports.
[59] K. Rock,et al. Both Dendritic Cells and Macrophages Can Stimulate Naive CD8 T Cells In Vivo to Proliferate, Develop Effector Function, and Differentiate into Memory Cells1 , 2005, The Journal of Immunology.
[60] K. Schroder,et al. Interferon- : an overview of signals, mechanisms and functions , 2004 .
[61] G. Trinchieri,et al. Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.
[62] M. Kelm. Nitric oxide metabolism and breakdown. , 1999, Biochimica et biophysica acta.
[63] T. Parmely,et al. An Interferon-γ-activated Site (GAS) Is Necessary for Full Expression of the Mouse iNOS Gene in Response to Interferon-γ and Lipopolysaccharide* , 1997, The Journal of Biological Chemistry.
[64] U. Boehm,et al. Cellular responses to interferon-gamma. , 1997, Annual review of immunology.
[65] D. Lopez,et al. The altered tumoricidal capacity of macrophages isolated from tumor- bearing mice is related to reduce expression of the inducible nitric oxide synthase gene , 1996, The Journal of experimental medicine.
[66] C. Nathan,et al. Role of interferon regulatory factor 1 in induction of nitric oxide synthase , 1994, The Journal of experimental medicine.
[67] C. Starnes,et al. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. , 1994, Pharmacology & therapeutics.
[68] C. Nathan,et al. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide , 1993, The Journal of experimental medicine.
[69] R. Rodriguiz,et al. Recombinant human interferon gamma therapy for osteopetrosis. , 1992, The Journal of pediatrics.
[70] C. Nathan,et al. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells , 1989, The Journal of experimental medicine.